Name:	txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.

No definition available.

Name:	txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.

No definition available.

Name:	txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The amount of milestone payments upon FDA approval.

No definition available.

Name:	txmd_MilestonePaymentUponFDAApproval
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The amount of milestone payments payable after release of first commercial batch.

No definition available.

Name:	txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The net sales amount as defined in license agreement for step-based royalty payments.

No definition available.

Name:	txmd_NetSalesAmountPerStepbasedRoyalty
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Number of issued patents.

No definition available.

Name:	txmd_NumberOfIssuedPatents
Namespace Prefix:	txmd_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

The amount of required milestone payments upon cumulative net sales of specified levels by the company and affiliates and permitted sublicensees.

No definition available.

Name:	txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The percent of the net sales to be paid as royalty per license agreement.

No definition available.

Name:	txmd_RoyaltyPercent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The first level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.

No definition available.

Name:	txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The third level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.

No definition available.

Name:	txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The second level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.

No definition available.

Name:	txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

Name:	us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

Name:	us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Name:	us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Amount of amortization of other deferred costs recognized in the income statement.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Name:	us-gaap_OtherAmortizationOfDeferredCharges
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=txmd_AnnoveraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsTopicalCreamMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: